Optimizing prophylactic antibiotic regimen in patients admitted for transrectal ultrasound-guided prostate biopsies: A prospective randomized study

Ahmed Fahmy, Hazem Rhashad, Mohamed Mohi, Ahmed Elabbadie, Ahmed Kotb, Ahmed Fahmy, Hazem Rhashad, Mohamed Mohi, Ahmed Elabbadie, Ahmed Kotb

Abstract

Background: Transrectal ultrasound-guided prostate biopsies (TRUSBx), in spite of being one of the most frequently performed urological office procedures, are associated with a spectrum of complications, most significantly including infection. The aim of the study is to evaluate the prevalence of fluoroquinolone-resistant bacteria in rectal swabs from our local population prior to TRUSBx and to identify risk factors among a patient population harboring fluoroquinolone-resistant organisms.

Methods: We prospectively included 541 men who were submitted for TRUSBx in our center from March 2011 to June 2015. The indications for TRUSBx were an elevated prostate-specific antigen level and/or abnormal digital rectal exam. All patients were randomly divided into two groups: Group 1 (n = 279 cases) who received standard empirical prophylactic antibiotics and Group 2 who received targeted prophylaxis based on a rectal swab culture and susceptibility result. Differences in risk factors between quinolone-resistant and nonresistant patients were compared. Univariate and multivariate analyses were performed to identify independent potential risk factors associated with fluoroquinolone-resistant rectal flora.

Results: Sixteen out of 271 men developed infectious complications after TRUSBx in the group receiving standard empirical prophylaxis (5.7%). No men in the group who received targeted prophylactic antibiotic guided by rectal swab developed infectious complications. Among the 262 patients who underwent prebiopsy rectal swab cultures, 76 men (29%) displayed fluoroquinolone-resistant rectal flora (29%). In the multivariate analysis, a history of antibiotic exposure before prostate biopsy was the only independent factor associated with an increased risk of fluoroquinolone resistance.

Conclusion: Determining the prevalence of fluoroquinolone resistance in rectal flora has important implications in the selection of targeted prophylactic antibiotic regimens. Antimicrobial profiles guided by rectal swabs may prove useful to optimize prophylaxis prior to TRUSBx; this strategy is effective at reducing the rates of infectious complications, including sepsis, especially in men at higher risk of infectious complications.

Keywords: Biopsy; Prophylactic antibiotic; Prostate biopsy; Transrectal.

Figures

Fig. 1
Fig. 1
Study cases. FQ, fluroquinolones; TRUSBx, transrectal ultrasound-guided prostate biopsies.
Fig. 2
Fig. 2
Antimicrobial susceptibility testing to fluoroquinolone-resistant strains.

References

    1. Challacombe B., Dasgupta P., Patel U., Amoroso P., Kirby R. Recognizing and managing the complications of prostate biopsy. BJU Int. 2011;108:1233–1234.
    1. Nam R.K., Saskin R., Lee Y., Liu Y., Law C., Klotz L.H. Increasing hospital admission rates for urological complications after transrectal ultrasound guided prostate biopsy. J Urol. 2010;183:963–968.
    1. Loeb S., van den Heuvel S., Zhu X., Bangma C.H., Schröder F.H., Roobol M.J. Infectious complications and hospital admissions after prostate biopsy in a European randomized trial. Eur Urol. 2012;61:1110–1114.
    1. Loeb S., Carter H.B., Berndt S., Ricker W., Schaeffer E.M. Complications of prostate biopsy: Data from SEER-Medicare. J Urol. 2011;186:1830–1834.
    1. Puig J., Darnell A., Bermúdez P., Malet A., Serrate G., Baré M. Transrectal ultrasound-guided prostate biopsy: is antibiotic prophylaxis necessary? Eur Radiol. 2006;16:939–943.
    1. Kapoor D.A., Klimberg I.W., Malek G.H., Wegenke J.D., Cox C.E., Patterson A.L. Single-dose oral ciprofloxacin versus placebo for prophylaxis during transrectal prostate biopsy. Urology. 1998;52:552–558.
    1. Aron M., Rajeev T.P., Gupta N.P. Antibiotic prophylaxis for transrectal needle biopsy of the prostate: a randomized controlled study. BJU Int. 2000;85:682–685.
    1. Ismail M., Saini A., Nigam R. Ciprofloxacin-resistant infection after transrectal ultrasonography-guided prostate biopsy: should we reassess our practice? BJU Int. 2011;108:305–306.
    1. Zaytoun O.M., Vargo E.H., Rajan R., Berglund R., Gordon S., Jones J.S. Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology. 2011;7:1035–1041.
    1. Akduman B., Akduman D., Tokgöz H., Erol B., Türker T., Ayoğlu F. Long-term fluoroquinolone use before the prostate biopsy may increase the risk of sepsis caused by resistant microorganisms. Urology. 2011;78:250–255.
    1. Liss M.A., Chang A., Santos R., Nakama-Peeples A., Peterson E.M., Osann K. Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol. 2011;185:1283–1288.
    1. Kehinde E.O., Al-Maghrebi M., Sheikh M., Anim J.T. Combined ciprofloxacin and amikacin prophylaxis in the prevention of septicemia after transrectal ultrasound guided biopsy of the prostate. J Urol. 2013;189:911–915.
    1. Adibi M., Hornberger B., Bhat D., Raj G., Roehrborn C.G., Lotan Y. Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol. 2013;189:535–540.
    1. Batura D., Rao G.G., Nielson P.B., Charlett A. Adding amikacin to fluoroquinolone-based antimicrobial prophylaxis reduces prostate biopsy infection rates. BJU Int. 2011;107:760–764.
    1. Simsir A., Kismali E., Mammadov R., Gunaydin G., Cal C. Is it possible to predict sepsis, the most serious complication in prostate biopsy? Urol Int. 2010;84:395–399.
    1. Aus G., Ahlgren G., Bergdahl S., Hugosson J. Infection after transrectal core biopsies of the prostate—Risk factors and antibiotic prophylaxis. Br J Urol. 1996;77:851–855.
    1. Williamson D.A., Barrett L.K., Rogers B.A., Freeman J.T., Hadway P., Paterson D.L. Infectious complications following transrectal ultrasound (TRUS) guided prostate biopsy: new challenges in the era of multi-drug resistant Escherichia coli. Clin Infect Dis. 2013;52:267–274.
    1. Abughosh Z., Margolick J., Goldenberg S.L., Taylor S.A., Afshar K., Bell R. A prospective randomized trial of povidone-iodine prophylactic cleansing of the rectum before transrectal ultrasound guided prostate biopsy. J Urol. 2013;189:1326–1331.
    1. Koc G., Un S., Filiz D.N., Akbay K., Yilmaz Y. Does washing the biopsy needle with povidone-iodine have an effect on infection rates after transrectal prostate needle biopsy? Urol Int. 2010;85:147–151.
    1. Heidenreich A., Bastian P.J., Bellmunt J., Bolla M., Joniau S., Mason M.D. European Association of Urology; Arnhem (NL): 2013. Guidelines on prostate cancer [Internet] [cited 2013 May 10]. Available from:
    1. Campeggi A., Ouzaid I., Xylinas E., Lesprit P., Hoznek A., Vordos D. Acute bacterial prostatitis after transrectal ultrasound-guided prostate biopsy: Epidemiological, bacteria and treatment patterns from a 4-year prospective study. Int J Urol. 2014;21:152–155.
    1. Duplessis C.A., Bavaro M., Simons M.P., Marguet C., Santomauro M., Auge B. Rectal cultures before transrectal ultrasound-guided prostate biopsy reduce post-prostatic biopsy infection rates. Urology. 2012;79:556–561.
    1. Taylor A.K., Zembower T.R., Nadler R.B., Scheetz M.H., Cashy J.P., Bowen D. Targeted antimicrobial prophylaxis using rectal swab cultures in men undergoing transrectal ultrasound guided prostate biopsy is associated with reduced incidence of postoperative infectious complications and cost of care. J Urol. 2012;187:1275–1279.
    1. Batura D., Rao G.G., Nielsen P.B. Prevalence of antimicrobial resistance in intestinal flora of patients undergoing prostatic biopsy: implications for prophylaxis and treatment of infections after biopsy. BJU Int. 2010;106:1017–1020.
    1. Kanafani Z.A., Mehio-Sibai A., Araj G.F., Kanaan M., Kanj S.S. Epidemiology and risk factors for extended-spectrum beta-lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control. 2005;33:326–332.
    1. Lautenbach E., Patel J.B., Bilker W.B., Edelstein P.H., Fishman N.O. Extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: Risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162–1171.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner